In August 2021 Finfeed changed from a website that covered ASX listed news to a website
that covered a select range of ASX
listed small cap Biotech stocks that we are personally invested in: find out more.
The old Finfeed website, and all of the old articles are kept here for record keeping purposes.VISIT NEW SITE
Immuron shares soar more than 20%
2 minute read
Immuron Ltd (ASX:IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens released extremely promising clinical results on Wednesday, resulting in the company’s shares surging more than 20%.
The positive results related to a recent study on the immuno-reactivity of its commercially available and over-the-counter gastrointestinal and digestive health supplement Travelan® to infectious Vibrio cholera strains from South-East Asia.
Sponsored by the US Department of Defence and funded through the Defence Health Agency, the study was performed at the Department of Enteric Diseases (DED), Armed Forces Research Institute of Medical Sciences (AFRIMS), an overseas laboratory of the Walter Reed Army Institute of Research (WRAIR) located in Bangkok, Thailand.
Expanding the extent of Travelan® applications
The goal was to investigate the breadth of Travelan®‘s immunological reactivity against pathogenic Vibrio cholera bacterial isolates.
Clinical isolates were collected from infected personnel located in Bangladesh, Cambodia, and Thailand, enabling researchers to gauge Travelan®‘s potential against bacterial strains typically seen in the field.
When compared to a placebo control, researchers found that the polyclonal antibodies comprising Immuron’s Travelan® product were reactive to all 71 clinical isolates from these infected individuals.
The ability of Travelan® to bind these bacteria highlights the broad-spectrum recognition by Travelan® of surface antigens on potentially debilitating and even life-threatening bacteria.
Positive impact on corporate profile
Immuron’s share price has surged on the back of this news, and Chief Executive Gary Jacob commented on broader investor sentiment in saying, “The response we have recently received from the investment community to our collaboration with the US Department of Defence has been quite extraordinary, and in my opinion, this is indicative of the high significance the investment community places on this collaborative effort.”
With regard to the impact these developments have on potential applications of Travelan®, Jacob said, “The work completed by our research collaborators at the WRAIR has provided the company with a comprehensive characterisation profile of our flagship product which clearly demonstrates the potential effectiveness of Travelan® and the Immuron technology platform to neutralise pathogenic gastrointestinal bacterial infections, and offers significant potential as a preventive treatment for US military personnel and civilians stationed or traveling in locations where such infections may be debilitating.”